Trial Profile
Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Status changed from recruiting to completed, According to results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology